This includes phentermine and novel GLP-1 medicines, including liraglutide (Ozempic) and tripeptide (Munjaro)
Following peripheral administration, exenatide has been shown to suppress food intake via vagal-dependent and vagal-independent pathways that result in the direct activation of GLP-1R in the central nervous system
Retatrutides top-line Phase 2 data showed higher mean body-weight reduction than tirzepatides landmark trial results
However, semaglutide has FDA-approved uses under specific brand names and indications, while retatrutide remains investigational
Want to Learn More about this Question
Yes, as with other incretin-based therapies, nausea, diarrhea, and reduced appetite are among the most commonly reported side effects, especially during dose escalation